Strand Therapeutics, a biotech company, has successfully closed a $153 million Series B funding round to further develop its innovative mRNA therapies, particularly focusing on cancer and chronic conditions. The lead asset, STX-001, is an intra-tumor self-replicating mRNA therapy designed to express the immunomodulatory protein IL-12. This latest round of funding, supported by major pharmaceutical players like Eli Lilly, Amgen, and Regeneron, boosts Strand’s total funding to over $250 million, following a $97 million Series A round in November 2022 and a $400,000 grant from the National Institutes of Health.
The primary goal of Strand Therapeutics is to develop programmable mRNA therapies, with STX-001 leading the way as an experimental construct aimed at altering the tumor microenvironment within solid tumors by inducing a systemic anti-cancer immune response. The unique approach of using self-replicating mRNA allows for precise control over the expression of therapeutic payloads, facilitating targeted and controlled delivery to specific locations within the body. STX-001 is currently undergoing a Phase I clinical trial in patients with advanced solid tumors, demonstrating promising treatment responses, including partial and complete responses.
In addition to STX-001, Strand is progressing its pipeline with STX-003, described as a groundbreaking systemically administrable mRNA therapy designed for tumor targeting. With a similar self-replicating mechanism and IL-12 payload, STX-003 is poised to enter patient dosing next year, presenting new opportunities for mRNA-based cancer therapeutics. However, despite these advancements, the biotech industry faces challenges, as recent policy decisions by Health Secretary Robert F. Kennedy Jr. have terminated several contracts related to mRNA vaccine technology, citing concerns over efficacy against respiratory infections like COVID and flu.
The decision to halt mRNA vaccine programs has raised uncertainties within the biotech community regarding the future of mRNA technology beyond vaccines. Experts fear that the political climate may impact research and development efforts in other areas, including cancer therapeutics. Paul Offit, a prominent figure in vaccine education, highlighted the risk of misinformation and political influences undermining scientific progress, potentially hindering the exploration of mRNA applications beyond vaccines. As the industry navigates these policy headwinds, companies like Strand Therapeutics continue to push boundaries in mRNA research, emphasizing the importance of innovation and perseverance in the face of challenges.
Key Takeaways:
– Strand Therapeutics secures significant Series B funding to advance novel mRNA therapies for cancer and chronic conditions.
– The company’s lead asset, STX-001, demonstrates promising results in reshaping tumor microenvironments to trigger anti-cancer immune responses.
– Policy decisions impacting mRNA vaccine technology raise concerns about potential implications for mRNA research in other therapeutic areas.
– Despite challenges, biotech companies like Strand Therapeutics remain committed to driving innovation in mRNA-based therapies.
Tags: biotech
Read more on biospace.com